Content reflects the views of the posting party and is provided for informational purposes only. It does not constitute a solicitation, recommendation, endorsement, or investment advice by BioTech Funding Portal. All content is subject to the portal’s Community Content Guidelines.
Energesis’ Energy Expenditure Approach to Obesity: Brown Fat, GLP-1s, and the Competitive Landscape
Energesis
GLP-1 drugs such as semaglutide and tirzepatide have changed the obesity treatment landscape. They have helped many people lose meaningful weight and have made obesity one of the most important areas in medicine today.
But we do not believe they are the end of the story.
The GLP-1 therapies work by reducing appetite and food intake. This can be effective, but it addresses only one side of the body-w...more
LSDs + protein deficiency: a $13B Market and Rising
The Fabry Market Is Bigger Than the Headlines, and the Platform Behind It Is Bigger Still
Every few months a new acquisition reminds the market that lysosomal storage disorders are quietly one of the most durable franchises in rare disease. BioMarin's $4.8B acquisition of Amicus in April 2026 was the latest. So it is worth doing the arithmetic out loud, from primary sources, on exactly how large t...more
Welcome to the BioTech Funding Portal
We’re so glad you’re here! If we seem new to you, it is because we are. We are also a new concept in crowdfunding, built exclusively for the life sciences. Our mission is to build a strong community around the scientists and entrepreneurs working to bring life-altering solutions to patients. We believe in the power of the collective to help turn crucial treatments and diagnostics into reality.
As ...more
Cultivating an ecosystem of trust through principled decision-making
Glafabra Therapeutics Receives FDA Acceptance for Face-to-Face INTERACT Meeting for GT-GLA-S03, Its Cell-Based Gene Therapy for Fabry Disease
Glafabra granted a face-to-face INTERACT meeting slated to occur July 16, 2026.
We will be discussing with the FDA key questions that will set the development path of our GT-GLA-S03 cell-based gene therapy for Fabry in its journey towards the market.
This milestone achievement was only made possible with the amazing contributions of the internal team and our contractors. Many thanks to Elizabeth W
Investor Education Resources Now Available
We’ve published a comprehensive set of investor education materials to help participants better understand how Regulation Crowdfunding works on the BioTech Funding Portal. These resources are intended to explain the mechanics of crowdfunding offerings, the role of a registered funding portal, and the regulatory framework governing issuers and investors. Whether you are new to crowdfunding or revie...more
